Patents by Inventor Fabian DOCAGNE

Fabian DOCAGNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTIBODY USEFUL IN NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS
    Publication number: 20180371082
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 27, 2018
    Inventors: Fabian DOCAGNE, Richard MACREZ, Denis VIVIEN, Karl-Uwe PETERSEN
  • Antibody useful in neurological or neurodegenerative disorders
    Patent number: 10072077
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: September 11, 2018
    Assignees: PAION DEUTSCHLAND, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE CAEN NORMANDIE
    Inventors: Fabian Docagne, Richard Macrez, Denis Vivien, Karl-Uwe Petersen
  • NOVEL ANTIBODY USEFUL IN NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS
    Publication number: 20160115230
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-as-partate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Application
    Filed: May 21, 2014
    Publication date: April 28, 2016
    Inventors: Fabian DOCAGNE, Richard MACREZ, Denis VIVIEN, Karl-Uwe PETERSEN